Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290787 | 0.80 | KMT2A (0.56) | MEN1KMT2ATP53ALDH1A1L3MBTL1 | |
| SCHEMBL806658 | 0.76 | KMT2A (0.67) | MEN1KMT2ATP53ALDH1A1POLB | |
| SCHEMBL18358944 | 0.72 | MMP2 (0.59) | MEN1KMT2AALDH1A1MMP2MMP9 | |
| SCHEMBL13026257 | 0.72 | MAPT (0.58) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL15145914 | 0.72 | RAB9A (0.63) | MEN1KMT2ATP53ALDH1A1L3MBTL1 | |
| SCHEMBL16290785 | 0.72 | RAB9A (0.63) | MEN1KMT2ATP53ALDH1A1L3MBTL1 | |
| SCHEMBL5127476 | 0.72 | MMP2 (0.80) | MMP2MMP9 | |
| SCHEMBL3364049 | 0.71 | MEN1 (0.61) | MEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL25334646 | 0.71 | MAPT (0.56) | MEN1KMT2AALDH1A1 | |
| SCHEMBL28101490 | 0.71 | RAB9A (0.66) | MEN1KMT2AALDH1A1POLBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-104220058-A | Serine racemase inhibitor | NAT UNIV CORP UNIV TOYAMA | 2014-12-17 | — | — | CN | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | SRR, PRSS1, ME1 | MEN1 1089/4885KMT2A 3922/4885TP53 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.